Introduction
============

Venous thromboembolism (VTE) is a major cause of pregnancy related mortality[@ref1] [@ref2] and morbidity.[@ref3] VTE increases the risk of permanent work related disability.[@ref4] Pregnancy increases the risk of VTE in women fivefold to sixfold compared with age matched controls.[@ref5] A positive family history for VTE further increases the risk of pregnancy associated VTE 3.7-fold to 8.5-fold.[@ref6] [@ref7] Hereditary thrombophilia increases the risk of pregnancy associated VTE up to 34-fold as reported by Robertson et al in a systematic review including nine studies in 2006.[@ref8] Women are at an even higher risk for pregnancy associated VTE in the six week postpartum period than during pregnancy.

Absolute risk estimates of pregnancy associated VTE in women with inherited thrombophilia mentioned in the American College of Chest Physicians' (ACCP) 2012 guidelines[@ref9] are based on a limited number of cohort studies, and on an estimated baseline VTE incidence multiplied by the odds ratios found in the systematic review by Robertson et al.[@ref8] To date, no systematic review or meta-analysis of absolute risk of pregnancy associated VTE for women with thrombophilia has been published. Data on risks of pregnancy associated VTE of compound heterozygous factor V Leiden and prothrombin G20210A mutation were not included in Robertson's systematic review[@ref8] nor in the ACCP 2012 guidelines.[@ref9] As several studies on thrombophilia and the risk of pregnancy associated VTE have been published since 2006, an updated systematic review is needed.

Owing to limitations of the data available, guidelines for the management of pregnant women with thrombophilia without previous VTE differ considerably in their recommendations on the use of thrombosis prophylaxis in the antepartum and postpartum period.[@ref10] We performed an updated systematic review and meta-analysis of studies on the relative and absolute risks of pregnancy associated VTE in women with established thrombophilia with no previous VTE to improve prevention of pregnancy associated VTE in women.

Methods
=======

The results of this systematic review and meta-analysis are reported according to PRISMA guidelines.[@ref11] Details of the study protocol are available in web appendix 1.

Data sources and searches
-------------------------

We systematically searched Embase, Medline, Web of Science, Cochrane Library, and Google Scholar using a search strategy constructed with the aid of a biomedical information specialist (see web appendix 1 for details). References were checked for additional articles missed by the primary search. The search was first performed on 8 February 2016 and updated on 14 November 2016. Two authors (FNC and JJD) independently selected articles for further reading. All articles were included or excluded based on predefined selection criteria. Decisions were based on consensus. Authors were contacted by email if clarification was required.

Study selection
---------------

Case-control studies or cohort studies that contained extractable information on the number of pregnancies and the outcome first VTE were eligible. The studies contained information on participants with specific inherited thrombophilias: antithrombin deficiency, protein C deficiency, protein S deficiency, factor V Leiden mutation (heterozygous or homozygous), prothrombin G20210A mutation (heterozygous or homozygous), or compound heterozygous factor V Leiden and prothrombin G20210A mutation. Studies were included if the definition of VTE was compatible with the following: VTE was considered established if it was confirmed by objective means, or when the patient had received a full course of a full dose anticoagulant treatment without objective testing. Studies contained data on pregnancies without use of anticoagulants. To minimise bias we excluded cohort studies that did not separate proband data from family member data. Studies were peer reviewed, written in English, and published between 1970 and 2016. In the event of duplicate publications, we chose the most informative report.

Data extraction and quality assessment
--------------------------------------

Data were extracted in duplicate using standardised forms. Disagreements were resolved by consensus. VTE events were deep venous thrombosis, pulmonary embolism, deep venous thrombosis and pulmonary embolism, or non-separately described superficial venous thrombosis events. Separately reported superficial venous thrombosis events were not considered as VTE events. In case-control studies, we recorded the number of women with the selected thrombophilia for each number of cases and for each number of respective controls. For each group in cohort studies, we recorded the number of pregnancy associated first VTE events for each number of pregnancies. These events were classified as antepartum or post partum if this information was available. For the calculation of odds ratios, in case-control studies we compared women with separate thrombophilias with their respective study controls and in cohort studies we compared women with separate thrombophilias with women without established thrombophilia (non-carriers). Information on women in cohort studies who carried less established thrombophilic abnormalities, such as MTHFR (methylenetetrahydrofolate reductase) mutations[@ref8] and associated hyperhomocysteinemia, was analysed in the non-carriers group. A family history of VTE influences the VTE risk,[@ref6] [@ref12] so we classified studies as family studies or non-family studies. Quality assessment was performed using the Newcastle-Ottawa Scale (NOS) scoring (see web appendix 1).[@ref13]

Statistical analysis
--------------------

Bayesian random effects meta-analysis was used to estimate odds ratios and absolute risks of VTE for each thrombophilia. See web appendix 2 for more information on the bayesian analysis used. Risk distributions are summarised by the median as a point estimate and 95% credible intervals (ie, area under the posterior distribution). Relatively non-informative priors were used for all variables (see web appendix 2). In addition, we estimated the probability of odds ratios and absolute risks being above thresholds of interest.[@ref14] For calculation of the absolute risk of postpartum VTE, we disregarded pregnancies that had resulted in a VTE antepartum. To handle partly missing information on time of VTE events, bayesian multiple imputation was used (ie, the assumption that data were missing completely at random)**.** Computations and graphics were performed with R.[@ref15] All bayesian computations were performed using the Marcov chain Monte Carlo (MCMC) sampler through Jags interface in R.[@ref16] MCMC sampling was run for each analysis for 1 500 000 iterations after discarding the first 50 000 iterations (burn-in).

Data synthesis and analysis
---------------------------

As a different absolute risk of pregnancy associated VTE was expected in non-carriers in family studies compared with non-family studies, we used the labels family study and non-family study as covariates in the analyses. In addition, the analyses of the absolute risks of pregnancy associated VTE in family studies and non-family studies are shown separately for women with thrombophilia and for non-carriers. We performed a sensitivity analysis by comparing the results of meta-analysis of all studies with the results of meta-analysis of studies remaining after elimination of studies not requiring objective VTE diagnoses (odds ratio only) and after elimination of low quality studies (defined as studies with a score below the median on the NOS). For the odds ratios, we also carried out separate case-control and cohort study analyses.

Patient involvement
-------------------

No patients were involved in setting the research question or the outcome measures, nor were they involved in developing plans for design or implementation of the study. No patients were asked to advise on interpretation or writing up of results. There are no plans to disseminate the results of the research to study participants or the relevant patient community. It was not evaluated whether the studies included in the review had any patient involvement.

Results
=======

Summary of selection process
----------------------------

The search yielded 2695 articles. We identified another eight articles for full review by checking references. After removal of duplicates, 1593 articles were screened on title and abstract for further reading. Figure 1[](#f1){ref-type="fig"} shows that a total of 118 articles were selected for full review. Eighty two articles were excluded for various reasons. Finally, 36 articles were selected for the systematic review and meta-analysis.

![**Fig 1** Study selection process](crof039837.f1){#f1}

Most studies covered a selection of the thrombophilias of interest. The following numbers of studies were included on the separate thrombophilias: antithrombin deficiency: four cohort studies [@ref17] [@ref18] [@ref19] [@ref20] and seven case-control studies[@ref21] [@ref22] [@ref23] [@ref24] [@ref25] [@ref26] [@ref27]; protein C deficiency: three cohort studies[@ref18] [@ref19] [@ref20] and eight case-control studies[@ref21] [@ref23] [@ref24] [@ref25] [@ref26] [@ref27] [@ref28] [@ref29]; protein S deficiency: three cohort studies[@ref18] [@ref19] [@ref20] and eight case-control studies[@ref21] [@ref22] [@ref23] [@ref24] [@ref25] [@ref26] [@ref27] [@ref29]; heterozygous factor V Leiden: 17 cohort studies[@ref7] [@ref30] [@ref31] [@ref32] [@ref33] [@ref34] [@ref35] [@ref36] [@ref37] [@ref38] [@ref39] [@ref40] [@ref41] [@ref42] [@ref43] [@ref44] [@ref45] and 11 case-control studies[@ref21] [@ref22] [@ref23] [@ref24] [@ref25] [@ref26] [@ref28] [@ref29] [@ref46] [@ref47] [@ref48]; homozygous factor V Leiden: six cohort studies[@ref7] [@ref30] [@ref31] [@ref43] [@ref45] [@ref49] and six case-control studies[@ref21] [@ref23] [@ref24] [@ref26] [@ref47] [@ref48]; heterozygous prothrombin G20210A mutation: five cohort studies[@ref31] [@ref32] [@ref39] [@ref50] [@ref51] and 10 case-control studies[@ref21] [@ref22] [@ref23] [@ref24] [@ref25] [@ref26] [@ref28] [@ref46] [@ref47] [@ref48]; homozygous prothrombin G20210A mutation: one cohort study[@ref31] and three case-control studies[@ref22] [@ref26] [@ref47]; and compound heterozygous factor V Leiden and prothrombin G20210A mutation: three cohort studies[@ref39] [@ref45] [@ref49] and five case-control studies.[@ref21] [@ref22] [@ref24] [@ref26] [@ref47]

Study characteristics
---------------------

Web appendix 1 summarises the study characteristics. The total number of pregnancies reported was 41 297, of which 5994 were in women with thrombophilia and 35 303 were in controls or non-carriers. Of 36 studies, 12 were case-control studies, 15 were family cohort studies, and nine were non-family cohort studies. Fourteen cohort studies were retrospective and 10 were prospective. Of 24 cohort studies, 15 contained data on the time of venous thromboembolism (VTE) events (antepartum or post partum).

Risk of bias within studies
---------------------------

Web appendix 2 provides details of study quality assessment as reflected by Newcastle-Ottawa Scale (NOS) scoring. The median of NOS scores was 8 in both case-control and cohort studies. Two cohort studies had no non-carrier group.[@ref18] [@ref41] Most studies required an objective VTE diagnosis. The six studies that allowed antithrombotic treatment without an objective VTE diagnosis were not given a star in the quality assessment score for selection of cases in case-control studies or for assessment of outcome in cohort studies.[@ref7] [@ref17] [@ref30] [@ref31] [@ref36] [@ref50]

Relative risk of pregnancy associated VTE
-----------------------------------------

Table 1[](#tbl1){ref-type="table"} summarises the meta-analyses of the relative risks of pregnancy associated VTE expressed as odds ratios. High odds ratios were found for antithrombin deficiency (9.5, 95% credible interval 1.6 to 31.9), protein C deficiency (9.3, 2.1 to 43.1), protein S deficiency (7.0, 1.3 to 21.9), heterozygous factor V Leiden mutation (6.4, 4.0 to 9.7), homozygous factor V Leiden (35.8, 0.4 to 137.8), heterozygous prothrombin G20210A mutation (5.1, 2.6 to 9.8), and compound heterozygous factor V Leiden and prothrombin G20210A mutation (21.2, 1.6 to 89.0). Odds ratios were high but not statistically significant for homozygous prothrombin G20210A mutation (21.1, 0.0 to 727.4). Web appendix 1 shows the forest plots for the odds ratio calculations.

###### 

Relative risk of venous thromboembolism (VTE) associated with pregnancy

  Thrombophilia                                                            No of women with thrombophilia, with VTE/Total\*   No of controls, with VTE/Total\*   Odds ratios (95% CrI)                           No of studies         Probability (%) of OR \>1 for high quality studies                                      
  ------------------------------------------------------------------------ -------------------------------------------------- ---------------------------------- ----------------------- ----------------------- --------------------- ---------------------------------------------------- --------------------- -- ---- ---- -----
  Antithrombin deficiency                                                  48/153                                             710/2178                           9.5 (1.6 to 31.9)       5.0 (0.6 to 24.7)       25.9 (0.0 to 176.3)   7.9 (1.2 to 25.5)                                    8.9 (0.3 to 34.7)        10   7    99
  Protein C deficiency                                                     49/180                                             691/2024                           9.3 (2.1 to 43.1)       12.3 (0.0 to 139.8)     5.9 (0.0 to 49.6)     9.3† (2.1 to 43.1)                                   7.7 (0.0 to 48.1)        10   6    99
  Protein S deficiency                                                     53/192                                             700/2212                           7.0 (1.3 to 21.9)       6.7 (0.2 to 34.7)       7.2 (0.0 to 35.4)     7.0\* (1.3 to 21.9)                                  6.9 (0.2 to 24.6)        10   7    91
  Heterozygous factor V Leiden mutation                                    305/3345                                           923/34 626                         6.4 (4.0 to 9.7)        7.2 (4.3 to 12.6)       3.9 (0.2 to 11.9)     5.9 (3.8 to 9.0)                                     6.4 (3.9 to 10.6)        27   21   100
  Homozygous factor V Leiden mutation                                      27/80                                              919/26 906                         35.8 (0.4 to 137.8)     128.9 (3.0 to 3093.9)   12.0 (0.0 to 69.9)    31.8 (0.2 to 145.3)                                  46.7 (4.1 to 193.1)      12   9    100
  Heterozygous prothrombin G20210A mutation                                94/1433                                            1002/21 736                        5.1 (2.6 to 9.8)        4.9 (2.0 to 11.4)       4.9 (0.0 to 23.7)     4.5 (2.2 to 8.5)                                     4.3 (2.0 to 8.8)         15   12   100
  Homozygous prothrombin G20210A mutation                                  4/5                                                559/19 692                         21.1 (0.0 to 727.4)     18.2 (0.0 to 1073.7)    NA                    14.8 (0.0 to 1052.9)                                 13.4 (0.0 to 584.2)      4    3    99
  Compound heterozygous factor V Leiden and prothrombin G20210A mutation   45/242                                             803/2652                           21.2 (1.6 to 89.0)      45.4 (0.6 to 478.6)     8.6 (0.5 to 62.3)     21.2† (1.6 to 89.0)                                  26.9 (1.1 to 147.1)      8    7    100

Odds ratios for pregnancy associated VTE for each thrombophilia compared with controls or non-carriers, including sensitivity analyses. Sensitivity analyses show meta-analyses for each study type, meta-analyses of only studies requiring an objective VTE diagnosis, and of only high quality studies (NOS score ≥8). Final column shows that the probability for the odds ratio being \>1 for high quality studies are ≥99% for all thrombophilias. CrI=credible interval, NOS=Newcastle-Ottawa scale, NA=not available. \*Case-control and cohorts with non-carriers group. †All studies for this thrombophilia required objectively confirmed VTE.

Absolute risk of pregnancy associated VTE
-----------------------------------------

Table 2[](#tbl2){ref-type="table"} summarises the results of the meta-analyses of absolute risks of pregnancy associated VTE for women with the separate thrombophilias. The forest plots are given in web appendix 1.

###### 

Absolute risks (AR) of pregnancy associated venous thromboembolism (VTE) for each thrombophilia, for family and non-family cohort studies

  Thrombophilia                                                             No of studies   No of women with thrombophilia with VTE/Total   No of VTE events with information on time of occurrence/Total      AR of VTE, all studies, % pregnancies (95% CrI)                       \% probability of AR \>1%, for all studies      \% probability of AR \>3%, for all studies         High quality studies                                
  ------------------------------------------------------------------------- --------------- ----------------------------------------------- --------------------------------------------------------------- -- ------------------------------------------------- ------------------- -------------------------------------------- -- -------------------------------------------- ----- ---------------------- ---- ---- -- ---- ---------- --------------------
  Antithrombin deficiency:                                                                                                                                                                                                                                                                                                                                                                                                                  
   Family                                                                   4               23/125                                          23/23                                                              16.6 (0.0 to 45.1)                                7.3 (1.8 to 15.6)   11.1 (3.7 to 21.0)                              100                                          100                          96   99      3    13/105     10.5 (0.0 to 30.3)
  Protein C deficiency:                                                                                                                                                                                                                                                                                                                                                                                                                     
   Family                                                                   3               10/137                                          10/10                                                              7.8 (0.0 to 33.8)                                 3.2 (0.6 to 8.2)    5.4 (0.9 to 13.8)                               96                                           99                           54   83      2    4/123      2.6 (0.0 to 13.5)
  Protein S deficiency:                                                                                                                                                                                                                                                                                                                                                                                                                     
   Family                                                                   3               7/135                                           7/7                                                                4.8 (0.0 to 20.0)                                 0.9 (0.0 to 3.7)    4.2 (0.7 to 9.4)                                47                                           98                           9    73      2    6/130      3.6 (0.0 to 37.0)
  Heterozygous factor V Leiden mutation:                                                                                                                                                                                                                                                                                                                                                                                                    
   Overall                                                                  17              45/3031                                         37/45                                                              1.1 (0.3 to 1.9)\*                                0.4 (0.1 to 0.9)    2.0 (0.9 to 3.7)                                2                                            97                           0    11      13   43/2604    1.3 (0.5 to 2.2)
   Family                                                                   8               35/1359                                         34/35                                                              2.4 (0.9 to 4.4)                                  0.4 (0.0 to 0.9)    2.5 (1.2 to 4.4)                                3                                            100                          0    25      6    33/1291    2.4 (0.6 to 5.4)
   Non-family                                                               9               10/1672                                         3/10                                                               0.4 (0.0 to 0.9)                                  0.7 (0.0 to 2.6)    0.4 (0.0 to 1.8)                                31                                           15                           4    2       7    10/1313    0.6 (0.0 to 1.2)
  Homozygous factor V Leiden mutation:                                                                                                                                                                                                                                                                                                                                                                                                      
   Overall                                                                  6               5/58                                            5/5                                                                6.2 (0.0 to 18.0)                                 2.8 (0.0 to 8.6)    2.8 (0.0 to 8.8)                                86                                           85                           47   46      5    5/56       7.9 (0.4 to 23.0)
   Family                                                                   3               4/35                                            4/4                                                                8.3 (0.0 to 29.6)                                 NA                  NA                                              NA                                           NA                           NA   NA      2    4/33       9.9 (0.0 to 39.7)
   Non-family                                                               3               1/23                                            1/1                                                                5.6 (0.0 to 34.3)                                 NA                  NA                                              NA                                           NA                           NA   NA      3    1/23       5.6 (0.0 to 34.3)
  Heterozygous prothrombin G20210A mutation:                                                                                                                                                                                                                                                                                                                                                                                                
   Overall                                                                  5               14/1322                                         9/14                                                               0.9 (0.2 to 2.0)                                  0.0 (0.0 to 0.2)    0.9 (0.2 to 2.0)                                0                                            41                           0    1       5    14/1322    0.9 (0.2 to 2.0)
   Family                                                                   4               11/998                                          9/11                                                               1.0 (0.0 to 2.5)                                  NA                  NA                                              NA                                           NA                           NA   NA      4    11/998     1.0 (0.0 to 2.5)
   Non-family                                                               1               3/324                                           0/3                                                                0.8 (0.1 to 2.0)                                  NA                  NA                                              NA                                           NA                           NA   NA      1    3/324      0.8 (0.1 to 2.0)
  Compound heterozygous factor V Leiden and prothrombin G20210A mutation:                                                                                                                                                                                                                                                                                                                                                                   
   Family                                                                   3               5/199                                           3/5                                                                2.5 (0.0 to 9.5)                                  NA                  NA                                              NA                                           NA                           NA   NA      3    5/199      2.5 (0.0 to 9.5)
  Non-carriers, overall:                                                                                                                                                                                                                                                                                                                                                                                                                    
   Family                                                                   13              14/2330                                         13/14                                                              0.5 (0.2 to 1.0)                                  NA                  NA                                              NA                                           NA                           NA   NA      12   12/2293    0.4 (0.1 to 0.8)
   Non-family                                                               9               20/31245                                        9/20                                                               0.1 (0.0 to 0.1)                                  NA                  NA                                              NA                                           NA                           NA   NA      7    18/30791   0.1 (0.0 to 0.1)

Analyses shown are meta-analyses of absolute risks of all studies, including absolute risk of antepartum VTE and postpartum VTE, and meta-analyses of high quality studies (NOS score ≥8) only. The probability of absolute risks of pregnancy associated VTE being above the treatment thresholds of 1% and 3% are also shown. CrI=credible interval, NOS=Newcastle-Ottawa scale, NA=not available. \*Significant effect of family studies as compared with non-family studies.

Antithrombin, protein C, and protein S deficiency
-------------------------------------------------

Only family studies were available for women with antithrombin, protein C, and protein S deficiency. The highest absolute risk of pregnancy associated VTE was found in antithrombin deficient women (overall: 16.6%, 95% credible interval 0.0% to 45.1%; antepartum: 7.3%, 1.8% to 15.6%; post partum: 11.1%, 3.7% to 21.0%). Absolute risks were also high for protein C deficiency (overall: 7.8%, 0.0% to 33.8%; antepartum: 3.2%, 0.6% to 8.2%; post partum: 5.4%, 0.9% to 13.8%), and protein S deficiency (overall: 4.8%, 0.0% to 20.0%; antepartum: 0.9%, 0.0% to 3.7%; post partum: 4.2%, 0.7% to 9.4%).

Heterozygous and homozygous factor V Leiden mutations
-----------------------------------------------------

For women with heterozygous factor V Leiden mutation, the absolute risk of pregnancy associated VTE was 1.1% overall (95% credible interval 0.3% to 1.9%), 0.4% antepartum (0.1% to 0.9%), and 2.0% postpartum (0.9% to 3.7%). The absolute risk of pregnancy associated VTE derived from family studies (2.4%) was higher than the risk derived from non-family studies (0.4%).

For women with homozygous factor V Leiden mutation, the absolute risk of pregnancy associated VTE was 6.2% overall (95% credible interval 0.0% to 18.0%), 2.8% antepartum (0.0% to 8.6%), and 2.8% post partum (0.0% to 8.8%). The absolute risk of pregnancy associated VTE derived from family studies (8.3%, 95% credible interval 0.0% to 29.6%) was higher than the risk derived from non-family studies (5.6%, 0.0% to 34.3%).

Heterozygous and homozygous prothrombin G20210A mutation
--------------------------------------------------------

For women with heterozygous prothrombin G20210A mutation, the absolute risk of pregnancy associated VTE was 0.9% overall (95% credible interval 0.2% to 2.0%), 0.0% antepartum (0.0% to 0.2%), and 0.9% post partum (0.2% to 2.0%). The absolute risk of pregnancy associated VTE derived from family studies (1.0%) was higher than the risk derived from non-family studies (0.8%).

The one woman with homozygous prothrombin G20210A mutation in the cohort study that qualified for inclusion did not have a VTE event.

Combined heterozygous factor V Leiden and prothrombin G20210A mutation
----------------------------------------------------------------------

For women with heterozygous factor V Leiden and prothrombin G20210A combined, the absolute risk of pregnancy associated VTE in family studies was 2.5% overall (95% credible interval 0.0% to 9.5%). Data were too limited for an analysis of antepartum and postpartum risk. No non-family studies without thrombosis prophylaxis were found.

Antepartum versus postpartum VTE
--------------------------------

Of 143 VTE events in cohort studies, information on time of occurrence was available for 115 events. Thirty events (26%) occurred antepartum and 85 (74%) occurred post partum. In high risk thrombophilias (antithrombin deficiency, protein C deficiency, protein S deficiency, and homozygous factor V Leiden mutation) 17/44 events (44%) occurred antepartum, and in low risk thrombophilias (heterozygous factor V Leiden, heterozygous prothrombin G20210A mutation, or compound heterozygous factor V Leiden and prothrombin G20210A mutation) or non-carriers 13/71 events (18%) occurred antepartum. For each thrombophilia the absolute risk of pregnancy associated VTE antepartum or post partum was calculated (table 2[](#tbl2){ref-type="table"}). As posterior distributions of the absolute risk estimates were skewed, the probabilities of absolute risks of pregnancy associated VTE being above the thresholds of 1% and 3% were calculated to aid in clinical decision making (table 2[](#tbl2){ref-type="table"}). We were not able to perform this analysis for compound heterozygous factor V Leiden and prothrombin G20210A mutation or for the family and non-family subgroups for homozygous factor V Leiden mutation or heterozygous prothrombin G20210A mutation owing to a lack of data.

Risk of bias across studies: additional and sensitivity analyses
----------------------------------------------------------------

In family studies on non-carriers the absolute risk of pregnancy associated VTE was higher (0.5%, 95% credible interval 0.2% to 1.0%) than in the non-family studies (0.1%, 0.0% to 0.2%). Table 1[](#tbl1){ref-type="table"} shows the results of the sensitivity analyses of relative risks. To investigate if study type (case-control *v* cohort) had an impact on odds ratio estimates, we performed separate analyses for these study types. Higher estimates were found in case-control studies for protein C deficiency, heterozygous factor V Leiden mutation, homozygous factor V Leiden mutation, and compound heterozygous factor V Leiden and prothrombin G20210A mutation. For antithrombin deficiency the odds ratio in cohort studies was higher. Table 1[](#tbl1){ref-type="table"} shows that removing studies which did not require objective VTE diagnoses had only limited impact on odds ratio estimates. To investigate if study quality had an impact on relative risk estimates of pregnancy associated VTE, the meta-analyses were repeated including only high quality studies (NOS score ≥8, ie, the median score). Table 1[](#tbl1){ref-type="table"} shows that similar odds ratio distributions and point estimates were obtained. The small number of pregnancies and VTE events for each study and variable results for each study cause skewed posterior distributions and hence statistical insignificance in the odds ratios for some thrombophilias. When calculating the probability of the odds ratios being greater than 1 in the high quality studies, for all thrombophilias we found a probability of 91% for protein S deficiency and 99% or higher for the others.

Table 2[](#tbl2){ref-type="table"} summarises the results of most sensitivity analyses of absolute risk estimates. To investigate if study quality had an impact on absolute risk estimates of pregnancy associated VTE, the meta-analyses were repeated including only high quality studies. Using this criterion, cohorts that lacked a non-carriers group (n=2) were also excluded. Web appendix 1 shows the results of all individual meta-analyses of high quality studies for all investigated thrombophilias. Overall, removal of low quality studies had an impact on the point estimates of absolute risks of pregnancy associated VTE, which are generally lower in studies with a high NOS score (≥8). However, the 95% credible intervals for all studies and for high quality studies remain similar for most thrombophilias.

Discussion
==========

Women with hereditary thrombophilia have an increased risk of pregnancy associated venous thromboembolism (VTE). High absolute risk estimates for pregnancy associated VTE were found for women with the rare thrombophilias of antithrombin deficiency, protein C deficiency, protein S deficiency, and homozygous factor V Leiden mutation, but not for compound heterozygous factor V Leiden and prothrombin G20210A mutation. For women with the more prevalent heterozygous factor V Leiden mutation or heterozygous prothrombin G20210A mutation the absolute risk was mildly increased, and limited to women with a positive family history. Most VTE occurred in the postpartum period. The absolute risk of pregnancy associated VTE was higher for non-carriers in family studies compared with non-carriers in non-family studies. Sensitivity analysis showed that point estimates and the 95% credible intervals of absolute risks were influenced by study quality in family cohort studies only. Compared with American College of Chest Physicians' (ACCP) guidelines,[@ref9] our meta-analysis of high quality studies shows markedly higher absolute risk estimates for women with antithrombin deficiency and protein C deficiency, and more conservative absolute risk estimates for women with protein S deficiency. In addition, high risks of pregnancy associated VTE were found for women with combined heterozygous factor V Leiden and prothrombin G20210A mutation. Antithrombin deficiency, protein C deficiency, protein S deficiency, homozygous factor V Leiden mutation, and homozygous prothrombin G20210A mutation should all be considered high risk thrombophilias for pregnant women based on our assessment of all studies and only high quality studies. In contrast, absolute risk estimates for heterozygous factor V Leiden and for heterozygous prothrombin G20210A mutation were lower compared with ACCP guidelines.[@ref9]

Strengths and weaknesses of this study
--------------------------------------

Bayesian statistics enabled us to perform both a meta-analysis of the relative risks and the first meta-analysis of the absolute risks of pregnancy associated VTE in women with thrombophilia. It allowed for calculating the antepartum and postpartum risk using multiple imputation when only partial information was available, and for calculating the probability for risks being greater than treatment thresholds. It is useful to take specific thresholds of interest into account, especially with skewed risk distributions as is the case in all analyses. 95% Credible intervals are not constructed the same way as in classic statistics (see web appendix 2). Therefore, the probability of the odds ratio being greater than 1 can still be above 99%, even though the 95% credible intervals include 1 (table 1[](#tbl1){ref-type="table"}). In contrast with classic statistics, bayesian statistics provide inferences that are conditional on the data and are exact. Therefore, interpretation of bayesian analysis is more straightforward and more direct in terms of belief (eg, a 95% credible interval for a risk is that region in which we believe the risk to be with a probability of 95%). Classic statistics' 95% confidence intervals describe the range where the exact risk estimate will be should the same experiment be repeated infinitely. Bayesian random effects meta-analysis is better able to compute study specific credible intervals depending on data from other studies.[@ref52] Bayesian analysis is the most suited method for this dataset of rare events: classic statistical methods cannot deal with infinite variance of individual studies, when event rates in a group of 0 or 100% occur.[@ref14] Most classic meta-analytical software automatically replace zero with a fixed value (typically 0.5). This usually has the undesirable effect of biasing study estimates.[@ref53] Regarding the studies included in our review, this issue would have occurred in all odds ratio estimates if classic meta-analysis software would have been used, but this poses no problem for bayesian analysis.

Odds ratio estimates correlate poorly with absolute risk estimates in our meta-analysis. This can be explained by differences of VTE risk in non-carriers. The absolute risk of pregnancy associated VTE for non-carriers from family studies is sixfold higher than the risk from non-family studies. Only the absolute risk of pregnancy associated VTE found in the non-family study non-carriers resembles the risk in the general population of 0.08% found by Simpson et al,[@ref54] whereas most odds ratio data stem from family studies and case-control studies. Controls from those studies do not resemble the general population, and therefore odds ratios are not easily translated to absolute risks in the general population.

The sensitivity analysis shows the impact of study quality on point estimates of VTE risk. This is most clear for the absolute risk of pregnancy associated VTE in women with deficiencies of antithrombin, protein C, or protein S. None the less, the meta-analyses including only high quality studies still show increased absolute risk estimates, with similar risk distributions (table 2[](#tbl2){ref-type="table"}). Overall, for women with high risk thrombophilias, risk estimates of pregnancy associated VTE have wide credible intervals. This is caused by the low number of women with rare thrombophilias investigated in studies and variable results between studies. All available data were used because the number of thrombotic events was low for the antepartum and postpartum analyses. For protein C and protein S deficiency, this causes a discrepancy between the antepartum, post partum, and high quality overall risk estimates, which could change treatment recommendations for protein C deficiency.

Non-family cohort studies rarely contain information on women with high risk thrombophilias. The data therefore provide little information on women with high risk thrombophilias who do not have a positive family history of VTE. The most recent study included in our review by Gerhardt et al[@ref21] was a case-control study that provided absolute VTE risk estimates in pregnant women with high risk thrombophilias regardless of family history. However, unusual cut-off values (40-90% of normal) for defining mild and severe deficiencies of antithrombin, protein C, and protein S were used. Furthermore, the calculation of absolute risk estimates from case-control data required making assumptions of the absolute risk in control women. The absolute VTE risk estimates for non-carriers in their analyses (0.105-0.20%) did not take family setting or non-family setting into account, which we have shown to differ significantly (0.5% *v* 0.1%).

A limitation of our meta-analysis is that it did not account for the changes in the methods of diagnosis of thrombophilia that have occurred, especially for protein S deficiency,[@ref55] as we were limited to the methods used in the individual studies. Preferably studies require objective diagnosis of VTE. Using studies that allowed treatment without objective diagnoses as a diagnostic criterion for VTE is not optimal. However, data on rare thrombophilias are sparse, and removing those studies in the sensitivity analysis of odds ratio estimates did not show major changes to the main results.

Strengths and weaknesses in relation to other studies
-----------------------------------------------------

This systematic review has identified the largest number of studies on thrombophilia and pregnancy associated VTE so far, including 41 297 pregnancies.[@ref8] [@ref56] [@ref57] [@ref58] When comparing the present review on thrombophilia and pregnancy associated VTE with the review by Robertson et al[@ref8] published in 2006, some differences should be appreciated. The review by Robertson et al included nine case-control studies, of which the latest was reported in 2003. Fifteen out of 36 studies included in our study predate 2003. This reflects a more inclusive search strategy. Our meta-analysis, based on more data, revealed higher odds ratios for pregnancy associated VTE for many thrombophilias, compared with controls. These differences between both reviews are important, as absolute risk estimates in current guidelines are mainly based on the review by Robertson et al.[@ref9] [@ref10] In the ACCP 2012 guidelines[@ref9] 10 additional studies have been reviewed.[@ref20] [@ref33] [@ref40] [@ref41] [@ref45] [@ref49] [@ref50] [@ref59] [@ref60] [@ref61] We excluded three of these additional studies because they failed to meet the inclusion criteria of "separate data per thrombophilia,"[@ref61] "objective VTE diagnosis,"[@ref60] and "no use of VTE prophylaxis."[@ref59] Nevertheless, our review included 36 studies, compared with 19 studies used in the ACCP 2012 guidelines. For women with deficiencies of antithrombin, protein C, or protein S, the results of our meta-analysis show notably higher relative and absolute risks of pregnancy associated VTE compared with those in the ACCP guidelines. Lower absolute risks were found for women with heterozygous factor V Leiden or heterozygous prothrombin G20210A mutation.

Recommendations
---------------

In order to determine an acceptable number of women needed to treat to prevent a VTE, the benefits of reducing the risk of pregnancy associated VTE through treatment must be weighed against the burdens of self injecting low molecular weight heparins during a certain period. However, efficacy and optimal doses of low molecular weight heparins prophylaxis are still a matter of debate.[@ref62] Using data on hip arthroplasty, the ACCP guidelines estimate the relative effects of prophylaxis using low molecular weight heparins in women.[@ref9] A 2014 Cochrane review found insufficient evidence on which to base recommendations for dose and duration of thrombosis prophylaxis during pregnancy and the postpartum period.[@ref63] To date, evidence on prophylaxis using low molecular weight heparins in pregnant women is insufficient to establish a number needed to treat. The results of current prospective studies in women with thrombophilia are eagerly awaited.[@ref64] [@ref65] In guidelines, thresholds for prophylaxis using low molecular weight heparins of the absolute risk of pregnancy associated VTE antepartum or postpartum vary from 1% to 3%.[@ref10] [@ref66] [@ref67] It must be considered that recommendations would differ considerably between thresholds of 1% or 3% (see web appendix 1). In the most recent guideline, experts set the threshold of the absolute risk of VTE for each antepartum or postpartum period at 3% by consensus.[@ref10] Therefore, for our recommendations we also used this threshold of 3% for each antepartum or postpartum period. We used all study data for our recommendations because credible intervals of all studies overlapped with those of high quality studies, and because more study data allowed for more precise risk estimates.

Based on the thresholds of 3% and our meta-analyses, the current ACCP 2012 guidelines[@ref9] and other guidelines as summarised by Bates et al[@ref10] can be challenged regarding thrombophilia. In the ACCP 2012 guidelines, prophylaxis using low molecular weight heparins in both the antepartum and postpartum period is only suggested for women with homozygous factor V Leiden or homozygous prothrombin G20210A mutations. We suggest antepartum prophylaxis and prophylaxis up to six weeks post partum for women with no previous VTE with antithrombin and protein C deficiency if they have a positive family history. For women with homozygous factor V Leiden mutations, thrombosis prophylaxis may be considered for women with a family history and additional risk factors for VTE, because the probabilities of antepartum and postpartum VTE risk are 47% and 46% respectively, and risk estimates from family studies are higher than the risk estimates from non-family studies. For women with protein S deficiency and a positive family history for VTE, we suggest prophylaxis using low molecular weight heparins only up to six weeks post partum. For homozygous prothrombin G20210A mutation we cannot give recommendations because of the lack of cohort data and the poor correlation of odds ratios with absolute risks. ACCP guidelines suggest thrombosis prophylaxis both antepartum and post partum.[@ref9]

In contrast with ACCP guidelines, for women with heterozygous factor V Leiden or heterozygous prothrombin G20210A mutations we suggest clinical vigilance only, even with a positive family history of VTE. The same applies for women with compound heterozygous factor V Leiden and prothrombin G20210A mutations. Additional personal risk factors for VTE such as obesity and immobilisation, should be taken into account when deciding on thrombosis prophylaxis in individual patients.

Conclusions
-----------

In this systematic review and meta-analysis we show that all women with inherited thrombophilia have an increased risk of pregnancy associated VTE. We have calculated high absolute risk estimates for pregnancy associated VTE for women with deficiency of antithrombin, protein C, or protein S and a positive family history for VTE, and for all women with homozygous factor V Leiden mutation. Although further research is needed for more precise risk estimates, in these women routine thrombosis prophylaxis should be considered. The risk estimates and chosen thresholds for treatment do not support routine use of thrombosis prophylaxis in women with heterozygous factor V Leiden or heterozygous prothrombin G20210A mutations or compound heterozygous factor V Leiden and prothrombin G20210A mutation. The data in this review should be considered in future management guidelines on pregnancy associated VTE risk in women with hereditary thrombophilia.

### What is already known on this topic

1.  Women with thrombophilia have an increased risk of pregnancy associated venous thrombosis (VTE)

2.  Absolute risk estimates vary considerably between studies and guidelines

3.  Guidance on whom should be given thrombosis prophylaxis varies considerably between guidelines

### What this study adds

1.  Thrombosis prophylaxis is generally not warranted for heterozygous factor V Leiden mutation, heterozygous prothrombin G20210A mutation, or compound heterozygous factor V Leiden and prothrombin G20210A mutation

2.  Antepartum and postpartum thrombosis prophylaxis is warranted in women with antithrombin deficiency or protein C deficiency and a positive family history of VTE

3.  Postpartum prophylaxis only is warranted for women with protein S deficiency

Extra material supplied by the author

###### 

**Appendix:** Supplementary materials

We thank Wichor Bramer from the Medical Library of the Erasmus University Medical Centre for his help in designing the search strategies.

Contributors: FNC conceived the study and prepared the initial manuscript. FNC and KN designed the study methods and performed the analysis. FNC and JJD identified the relevant studies. All authors revised the manuscript, read and approved the final manuscript, and are accountable for all aspects of the work, including the accuracy and integrity. FNC is the guarantor.

Funding: No external funding was provided.

Competing interests: All authors have completed the ICMJE uniform disclosure form at [www.icmje.org/coi_disclosure.pdf](http://www.icmje.org/coi_disclosure.pdf) (available on request from the corresponding author) and declare: no support from any organisation for the submitted work; no financial relationships with any organisation that might have an interest in the submitted work in the previous three years. MJHAK received research funding from Ferring Pharmaceuticals, Pfizer, Daiichi Sankyo, Boehringer Ingelheim, Bayer Nederland, and Pfizer Nederland. KM received research support from Bayer, Baxter, Sanquin, and Pfizer; speaker fees from Bayer, Sanquin, Boehringer Ingelheim, and Bristol-Myers Squibb; and consulting fees from Uniqure. FWGL received consulting fees from Uniqure, Shire, and Novonordisk (fees go to the institution); unrestricted research grants from CSL Behring and Baxalta (Shire); and travel support from Roche.

Ethical approval: Not required.

Data sharing: The data from this study and statistical code are available from the corresponding author at f.croles\@erasmusmc.nl.

Transparency: The manuscript's guarantor (FNC) affirms that the manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned have been explained.
